» Articles » PMID: 36416098

Real-Time Continuous Glucose Monitoring in Adolescents and Young Adults With Type 2 Diabetes Can Improve Quality of Life

Overview
Specialty Endocrinology
Date 2022 Nov 23
PMID 36416098
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Real-time continuous glucose monitoring (CGM) is effective for diabetes management in cases of type 1 diabetes and adults with type 2 diabetes (T2D) but has not been assessed in adolescents and young adults (AYAs) with T2D. The objective of this pilot interventional study was to assess the feasibility and acceptability of real-time CGM use in AYAs with T2D.

Methods: Adolescents and young adults (13-21 years old) with T2D for six months or more and hemoglobin A1c (A1c) greater than 7%, on any Food and Drug Administration-approved treatment regimen, were included. After a blinded run-in period, participants were given access to a real-time CGM system for 12 weeks. The use and acceptability of the real-time CGM were evaluated by sensor usage, surveys, and focus group qualitative data.

Results: Participants' (n = 9) median age was 19.1 (interquartile range [IQR] 16.8-20.5) years, 78% were female, 100% were people of color, and 67% were publicly insured. Baseline A1c was 11.9% (standard deviation ±2.8%), with median diabetes duration of 2.5 (IQR 1.4-6) years, and 67% were using insulin. Seven participants completed the study and demonstrated statistically significant improvement in diabetes-related quality of life, with the mean Pediatric Quality of Life inventory (PedsQL) diabetes score increasing from 70 to 75 after using CGM ( = .026). Focus group results supported survey results that CGM use among AYAs with T2D is feasible, can improve quality of life, and has the potential to modify behavior.

Conclusion: Real-time CGM is feasible and acceptable for AYAs with T2D and may improve the quality of life of patients with diabetes. Larger randomized controlled trials are needed to assess the effects on glycemic control and healthy lifestyle changes.

Citing Articles

14. Children and Adolescents: Standards of Care in Diabetes-2025.

Diabetes Care. 2024; 48(Supplement_1):S283-S305.

PMID: 39651980 PMC: 11635046. DOI: 10.2337/dc25-S014.


7. Diabetes Technology: Standards of Care in Diabetes-2025.

Diabetes Care. 2024; 48(Supplement_1):S146-S166.

PMID: 39651978 PMC: 11635043. DOI: 10.2337/dc25-S007.


Effectiveness of continuous glucose monitoring in patient management of Type 2 Diabetes Mellitus: an umbrella review of systematic reviews from 2011 to 2024.

Tan Y, Suan E, Koh G, Suhairi S, Tyagi S Arch Public Health. 2024; 82(1):231.

PMID: 39623499 PMC: 11610123. DOI: 10.1186/s13690-024-01459-2.


Acceptability and experiences of real-time continuous glucose monitoring in adults with type 2 diabetes using insulin: a qualitative study.

Sergel-Stringer O, Wheeler B, Styles S, Boucsein A, Lever C, Paul R J Diabetes Metab Disord. 2024; 23(1):1163-1171.

PMID: 38932793 PMC: 11196444. DOI: 10.1007/s40200-024-01403-9.


Barriers and Facilitators to Uptake of Continuous Glucose Monitoring for Management of Type 2 Diabetes Mellitus in Youth.

Peyyety V, Zupa M, Hewitt B, Rodriguez Gonzalez A, Mani I, Prioleau T Sci Diabetes Self Manag Care. 2023; 49(6):426-437.

PMID: 37927056 PMC: 10895543. DOI: 10.1177/26350106231205030.


References
1.
Boland E, Tamborlane W . Continuous glucose monitoring in youth with type 2 diabetes: overcoming barriers to successful treatment. Diabetes Technol Ther. 2001; 2 Suppl 1:S53-9. DOI: 10.1089/15209150050214131. View

2.
Park C, Le Q . The Effectiveness of Continuous Glucose Monitoring in Patients with Type 2 Diabetes: A Systematic Review of Literature and Meta-analysis. Diabetes Technol Ther. 2018; 20(9):613-621. DOI: 10.1089/dia.2018.0177. View

3.
Danne T, Nimri R, Battelino T, Bergenstal R, Close K, DeVries J . International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017; 40(12):1631-1640. PMC: 6467165. DOI: 10.2337/dc17-1600. View

4.
Nadeau K, Anderson B, Berg E, Chiang J, Chou H, Copeland K . Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities. Diabetes Care. 2016; 39(9):1635-42. PMC: 5314694. DOI: 10.2337/dc16-1066. View

5.
Anderson J, Gavin J, Kruger D . Current Eligibility Requirements for CGM Coverage Are Harmful, Costly, and Unjustified. Diabetes Technol Ther. 2019; 22(3):169-173. PMC: 7047118. DOI: 10.1089/dia.2019.0303. View